NO20090368L - Cyanocobalamin low viscosity aqueous formulations for intranasal delivery - Google Patents
Cyanocobalamin low viscosity aqueous formulations for intranasal deliveryInfo
- Publication number
- NO20090368L NO20090368L NO20090368A NO20090368A NO20090368L NO 20090368 L NO20090368 L NO 20090368L NO 20090368 A NO20090368 A NO 20090368A NO 20090368 A NO20090368 A NO 20090368A NO 20090368 L NO20090368 L NO 20090368L
- Authority
- NO
- Norway
- Prior art keywords
- cyanocobalamin
- solution
- csf
- low viscosity
- aqueous formulations
- Prior art date
Links
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 title abstract 20
- 235000000639 cyanocobalamin Nutrition 0.000 title abstract 10
- 239000011666 cyanocobalamin Substances 0.000 title abstract 10
- 229960002104 cyanocobalamin Drugs 0.000 title abstract 10
- 239000013011 aqueous formulation Substances 0.000 title 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract 4
- 239000000243 solution Substances 0.000 abstract 3
- 229930003779 Vitamin B12 Natural products 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 2
- 238000010255 intramuscular injection Methods 0.000 abstract 2
- 239000007927 intramuscular injection Substances 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 239000011715 vitamin B12 Substances 0.000 abstract 2
- 235000019163 vitamin B12 Nutrition 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En stabil farmasøytisk vannholdig løsning av cyanokobalamin omfattende cyanokobalamin og vann hvor nevnte løsning av cyanokobalamin er egnet for intranasal administrasjon, har en viskositet mindre enn omkring 1000 cPs, og gir en biotilgjengelighet av cyanokobalamin når administrert intranasalt på minst omkring 5% relativ til en intramuskulær injeksjon av cyanokobalamin. Den foreliggende oppfinnelsen er også rettet mot en fremgangsmåte for å heve vitamin B12 nivåene i den cerebrale spinalvæsken (CSF) omfattende å administrere intranasalt en tilstrekkelig mengde av en cyanokobalamin løsning for å øke det gjennomsnittlige forholdet av vitamin Bl2 i CSF i forhold til det i blodserumet (Bl2 CSF/B12 serum x 100) til minst omkring 1,1, omfattende intranasalt å administrere en vannholdig løsning av cyanokobalamin, hvor nevnte løsning av cyanokobalamin har en biotilgjengelighet på minst 5% relativ til en intramuskulær injeksjon av et cyanokobalamin.A stable pharmaceutical aqueous solution of cyanocobalamin comprising cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration has a viscosity of less than about 1000 cps and provides a bioavailability of cyanocobalamin when administered intranasally of at least about 5% relative to an intramuscular injection. of cyanocobalamin. The present invention is also directed to a method of raising vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a cyanocobalamin solution to increase the average ratio of vitamin B12 in CSF to that in the blood serum. (Bl2 CSF / B12 serum x 100) to at least about 1.1, comprising intranasally administering an aqueous solution of cyanocobalamin, wherein said solution of cyanocobalamin has a bioavailability of at least 5% relative to an intramuscular injection of a cyanocobalamin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2006/024685 WO2007149098A1 (en) | 2006-06-23 | 2006-06-23 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20090368L true NO20090368L (en) | 2009-03-23 |
Family
ID=38833714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090368A NO20090368L (en) | 2006-06-23 | 2009-01-23 | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2035441A4 (en) |
| JP (1) | JP5769924B2 (en) |
| KR (3) | KR20140101010A (en) |
| CN (1) | CN101600729A (en) |
| AU (1) | AU2006344733B2 (en) |
| CA (1) | CA2656823C (en) |
| IL (2) | IL196038A (en) |
| NO (1) | NO20090368L (en) |
| WO (1) | WO2007149098A1 (en) |
| ZA (1) | ZA200900191B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2632430T3 (en) * | 2010-10-29 | 2018-11-30 | Troikaa Pharmaceuticals Ltd | Nasal compositions of vitamin b12 |
| IL269069B (en) * | 2017-03-02 | 2022-09-01 | Dutch Renewable Energy B V | Intranasal administration of physiologically active substances |
| WO2022026762A1 (en) * | 2020-07-29 | 2022-02-03 | Lido Ventures Llc | Apparatus, system, and method for facilitating intranasal treatment of a patient |
| WO2025003468A1 (en) | 2023-06-30 | 2025-01-02 | Dutch Renewable Energy B.V. | Vitamin b12 formulation for intranasal administration |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE70180T1 (en) * | 1985-04-16 | 1991-12-15 | Nastech Pharm Co | AEROSOL FOR NOSE DUSTING OF VITAMIN B 12. |
| US4724231A (en) * | 1985-04-16 | 1988-02-09 | Nastech Pharmaceutical, Inc. | Nasel compositions containing vitamin B12 |
| US5112804A (en) * | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
| US4959176A (en) * | 1988-04-29 | 1990-09-25 | Beckman Instruments, Inc. | High resolution non corrosive amino acid analysis buffer solutions |
| US5227311A (en) * | 1988-10-11 | 1993-07-13 | Abbott Laboratories | Intrinsic factor to determine B12 |
| BE1007839A6 (en) * | 1993-12-20 | 1995-10-31 | Merkus Franciscus W H M Prof | PHARMACEUTICAL COMPOSITION FOR THE NASAL ADMINISTRATION OF HYDROXOCOBALAMINE. |
| US6406730B1 (en) * | 1998-12-01 | 2002-06-18 | Carl E. Banyard | Process for producing low acid food products |
| FR2787029A1 (en) * | 1998-12-09 | 2000-06-16 | Biovector Therapeutics | USE IN A PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION OF VITAMIN B12 FOR THE DELIVERY OF ACTIVE AGENTS TO THE CENTRAL NERVOUS SYSTEM |
| ATE380541T1 (en) * | 2000-09-20 | 2007-12-15 | Nycomed Pharma As | PRODUCTION OF VITAMIN EMULSIONS AND CONCENTRATES THEREOF |
| US20060074034A1 (en) * | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
| US6911434B2 (en) * | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
| DE10300719A1 (en) * | 2003-01-11 | 2004-07-22 | Basf Ag | Improved process for the production of vitamin B12 |
| US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
| US20060046969A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Antibacterial compositions for drug administration |
| JP2009504767A (en) * | 2005-08-17 | 2009-02-05 | フレミング・アンド・カンパニー・ファーマシューティカルズ | Vitamin B12 nasal spray and method of use |
-
2006
- 2006-06-23 KR KR1020147021098A patent/KR20140101010A/en not_active Ceased
- 2006-06-23 AU AU2006344733A patent/AU2006344733B2/en not_active Ceased
- 2006-06-23 CA CA2656823A patent/CA2656823C/en not_active Expired - Fee Related
- 2006-06-23 WO PCT/US2006/024685 patent/WO2007149098A1/en not_active Ceased
- 2006-06-23 EP EP06785533A patent/EP2035441A4/en not_active Ceased
- 2006-06-23 JP JP2009516468A patent/JP5769924B2/en not_active Expired - Fee Related
- 2006-06-23 CN CNA2006800556586A patent/CN101600729A/en active Pending
- 2006-06-23 KR KR1020177023153A patent/KR20170098977A/en not_active Ceased
- 2006-06-23 KR KR1020097001414A patent/KR20090074722A/en not_active Ceased
-
2008
- 2008-12-18 IL IL196038A patent/IL196038A/en active IP Right Grant
-
2009
- 2009-01-09 ZA ZA2009/00191A patent/ZA200900191B/en unknown
- 2009-01-23 NO NO20090368A patent/NO20090368L/en not_active Application Discontinuation
-
2016
- 2016-10-21 IL IL248447A patent/IL248447B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006344733A1 (en) | 2007-12-27 |
| IL248447A0 (en) | 2016-11-30 |
| JP5769924B2 (en) | 2015-08-26 |
| CA2656823C (en) | 2015-02-03 |
| AU2006344733B2 (en) | 2014-02-27 |
| KR20170098977A (en) | 2017-08-30 |
| KR20140101010A (en) | 2014-08-18 |
| WO2007149098A1 (en) | 2007-12-27 |
| IL196038A (en) | 2016-10-31 |
| JP2009541312A (en) | 2009-11-26 |
| ZA200900191B (en) | 2012-09-26 |
| KR20090074722A (en) | 2009-07-07 |
| CN101600729A (en) | 2009-12-09 |
| IL196038A0 (en) | 2009-09-01 |
| EP2035441A4 (en) | 2013-01-16 |
| CA2656823A1 (en) | 2007-12-27 |
| IL248447B (en) | 2021-10-31 |
| EP2035441A1 (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA92470C2 (en) | Dihydropteridinone infusion solution having a long shelf life | |
| WO2009105432A3 (en) | Devices and methods for delivery of a therapeutic agent through a pneumostoma | |
| NO20054711L (en) | Methods and pharmaceutical compositions for the palpable uptake of acceptable serum testosterone levels | |
| WO2004105702A3 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
| MX343867B (en) | Methods for administering weight loss medications. | |
| MY160074A (en) | Protopanaxadiol-type ginsenoside compositions and uses thereof | |
| WO2007002572A3 (en) | Nattokinase for reducing whole blood viscosity | |
| WO2006039704A3 (en) | Pharmaceutical composition and method for treating a joint capsule arthropathy | |
| NO20090368L (en) | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery | |
| BRPI0111591B8 (en) | compound, pharmaceutical composition, and uses of a compound | |
| IL194883A0 (en) | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol | |
| DE602008006700D1 (en) | ||
| BRPI0520493A2 (en) | uses of an enzyme, antifolate compound and folate pathway rescue agent, therapeutic system, and ex vivo methods to cleave a terminal l-glutamate group of a compound to determine cleavage rate and / or extent of a compound and to cleave a compound | |
| UA102254C2 (en) | Normal;heading 1;heading 2;heading 3;LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE | |
| UA102187C2 (en) | Diindolylmethane-containing pharmaceutical composition for oral administration | |
| JP2009504767A (en) | Vitamin B12 nasal spray and method of use | |
| ATE475484T1 (en) | DOSING DEVICE | |
| DK1883387T3 (en) | Container for liquid drugs to be administered | |
| WO2005020959A3 (en) | Novel drug compositions and dosage forms of topiramate | |
| NO20065453L (en) | Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases. | |
| WO2002070014A8 (en) | Compositions comprising an o/w emulsion containing conjugated linoleic acid | |
| WO2009051217A1 (en) | Fentanyl-containing percutaneous absorption preparation | |
| NO20061417L (en) | Acid-containing oxaliplatin formulations | |
| WO2009061445A3 (en) | Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction | |
| WO2013166246A3 (en) | Formulation and method to induce a deep state of relaxation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ENDO PHARMACEUTICALS INC, US |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |